T4090 vs Rhopressa for Glaucoma

Recruiting in Palo Alto (17 mi)

+22 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Laboratoires Thea

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The main purpose is to compare the ocular hypotensive efficacy and safety of two concentrations of T4090 (Kinezodianone R HCl 0.2% and 0.3%) ophthalmic solution with Rhopressa® ophthalmic solution

Research Team

Eligibility Criteria

This trial is for adults over 18 with Open-Angle Glaucoma or Ocular Hypertension in both eyes. Participants must understand the study and sign a consent form.

Inclusion Criteria

Informed consent dated and signed.

I am 18 years old or older.

I have been diagnosed with glaucoma or high eye pressure in both eyes.

Exclusion Criteria

I have a specific type of glaucoma not caused by an eye injury.

My glaucoma is in an advanced stage.

I have not had eye trauma, infection, or significant inflammation in the last 6 months.

See 2 more

Treatment Details

Interventions

Rhopressa® (Other)
T4090 (Other)

Trial OverviewThe trial aims to compare the effectiveness and safety of two concentrations (0.2% and 0.3%) of T4090 ophthalmic solution against Rhopressa® in reducing eye pressure.

Participant Groups

3Treatment groups

Experimental Treatment

Active Control

Group I: T4090 0.3%Experimental Treatment1 Intervention

Group II: T4090 0.2%Experimental Treatment1 Intervention

Group III: Rhopressa®Active Control1 Intervention